Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Accumulated Expenses: 2015-2023

Historic Other Accumulated Expenses for Iovance Biotherapeutics (IOVA) over the last 5 years, with Dec 2023 value amounting to $6.6 million.

  • Iovance Biotherapeutics' Other Accumulated Expenses fell 7.25% to $4.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $4.0 million, marking a year-over-year decrease of 7.25%. This contributed to the annual value of $6.6 million for FY2023, which is N/A change from last year.
  • As of FY2023, Iovance Biotherapeutics' Other Accumulated Expenses stood at $6.6 million, which was up 1,248.26% from $489,000 recorded in FY2018.
  • Iovance Biotherapeutics' 5-year Other Accumulated Expenses high stood at $6.6 million for FY2023, and its period low was $6.6 million during FY2023.
  • For the 1-year period, Iovance Biotherapeutics' Other Accumulated Expenses averaged around $6.6 million, with its median value being $6.6 million (2023).